TY - JOUR
T1 - KEYNOTE-975 study design
T2 - A Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
AU - Shah, Manish A.
AU - Bennouna, Jaafar
AU - Doi, Toshihiko
AU - Shen, Lin
AU - Kato, Ken
AU - Adenis, Antoine
AU - Mamon, Harvey J.
AU - Moehler, Markus
AU - Fu, Xiaolong
AU - Cho, Byoung Chul
AU - Bordia, Sonal
AU - Bhagia, Pooja
AU - Shih, Chie Schin
AU - Desai, Anjali
AU - Enzinger, Peter
N1 - Publisher Copyright:
© 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
PY - 2021/4
Y1 - 2021/4
N2 - Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in patients ineligible for surgical resection, but survival outcomes are poor. Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. Here, we describe the design and rationale for the double-blind, Phase III, placebo-controlled, randomized KEYNOTE-975 trial investigating pembrolizumab in combination with definitive chemoradiotherapy as first-line treatment in patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer.
AB - Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in patients ineligible for surgical resection, but survival outcomes are poor. Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. Here, we describe the design and rationale for the double-blind, Phase III, placebo-controlled, randomized KEYNOTE-975 trial investigating pembrolizumab in combination with definitive chemoradiotherapy as first-line treatment in patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer.
UR - http://www.scopus.com/inward/record.url?scp=85102037448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102037448&partnerID=8YFLogxK
U2 - 10.2217/fon-2020-0969
DO - 10.2217/fon-2020-0969
M3 - Article
C2 - 33533655
AN - SCOPUS:85102037448
SN - 1479-6694
VL - 17
SP - 1143
EP - 1153
JO - Future Oncology
JF - Future Oncology
IS - 10
ER -
